Terms: = Testicular cancer AND APC, DP2, 324, ENSG00000134982, P25054, FPC, GS, DP3, DP2_5 AND Prognosis
6 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Differences Between Surveillance and Active Treatment After Initial Orchiectomy in Patients With Stage I Mixed Germ Cell Tumors of the Testis: A Propensity Score Matching Analysis.
Du Y; Liu L; Zou B; Chen Z; Chen Q; Deng R; Yang P
J Surg Res; 2024 Feb; 294():26-36. PubMed ID: 37857140
[TBL] [Abstract] [Full Text] [Related]
3. testicular cancer in Geneva, Switzerland, 1970-2012: incidence trends, survival and risk of second cancer.
Schaffar R; Pant S; Bouchardy C; Schubert H; Rapiti E
BMC Urol; 2019 Jul; 19(1):64. PubMed ID: 31291913
[TBL] [Abstract] [Full Text] [Related]
4. testicular cancer mortality in Brazil: trends and predictions until 2030.
Soares SCM; Dos Santos KMR; de Morais Fernandes FCG; Barbosa IR; de Souza DLB
BMC Urol; 2019 Jul; 19(1):59. PubMed ID: 31277621
[TBL] [Abstract] [Full Text] [Related]
5. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer.
de Haas EC; Zwart N; Meijer C; Suurmeijer AJ; Meijer K; Guchelaar HJ; Hoekstra HJ; van Leeuwen FE; Sleijfer DT; Boezen HM; Gietema JA
Cancer; 2010 Dec; 116(24):5628-36. PubMed ID: 20737565
[TBL] [Abstract] [Full Text] [Related]
6. Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma.
Horwich A; Wilson C; Cornes P; Gildersleve J; Dearnaley D
Eur Urol; 1993; 23(1):219-22. PubMed ID: 8386653
[TBL] [Abstract] [Full Text] [Related]
